Basit öğe kaydını göster

dc.contributor.authorAktas, Gülseren
dc.date.accessioned2021-03-02T23:20:30Z
dc.date.available2021-03-02T23:20:30Z
dc.date.issued2017
dc.identifier.citationAktas G., "In-vitro activity of ceftriaxone combined with newer agents against MRSA", JOURNAL OF CHEMOTHERAPY, cilt.29, sa.6, ss.383-385, 2017
dc.identifier.issn1120-009X
dc.identifier.otherav_11dc5c06-ee37-446e-80a7-45b64fcfa1fc
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/17471
dc.identifier.urihttps://doi.org/10.1080/1120009x.2016.1246633
dc.description.abstractIn this study, in vitro synergism in combinations of agents as ceftriaxone/dalbavancin, ceftriaxone/linezolid and ceftriaxone/daptomycin against MRSA strains were investigated. Thirty clinical MRSA strains were tested. The minimum inhibitory concentrations of all antibiotics were determined using reference broth microdilution method. In-vitro activities of antibiotics combined against the strains were tested using two-dimensional checkerboard microdilution method. Results were interpreted as follows: synergy = FICI 0.5-4. The MIC50, MIC90 and MICrange of ceftriaxone, daptomycin, dalbavancin and linezolid were found as 128, 1024 and 16-2048 mg/L; 1, 1 and 0.5-1 mg/L; 0.12, 0.12 and 0.03-0.12 mg/L; and 1, 2 and 1-2 mg/L, respectively. Our results showed that the frequency of synergistic effects (FICI: 4) was observed.
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectBiyokimya
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectCerrahi Tıp Bilimleri
dc.subjectPatoloji
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectBULAŞICI HASTALIKLAR
dc.subjectİmmünoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectPATOLOJİ
dc.subjectBiyoloji ve Biyokimya
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.titleIn-vitro activity of ceftriaxone combined with newer agents against MRSA
dc.typeMakale
dc.relation.journalJOURNAL OF CHEMOTHERAPY
dc.contributor.departmentİstanbul Üniversitesi , İstanbul Üniversitesi, İstanbul Tıp Fakültesi, , Temel Tıp Bilimleri
dc.identifier.volume29
dc.identifier.issue6
dc.identifier.startpage383
dc.identifier.endpage385
dc.contributor.firstauthorID97050


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster